<DOC>
	<DOC>NCT00234923</DOC>
	<brief_summary>The purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of Kaletra single agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm</brief_summary>
	<brief_title>Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<criteria>Antiretroviral naïve HIV RNA &lt;100,000 copies/mL CD4 cell count &gt;100 cells/mL at screening with Karnofsky Score &gt; 70 If female, nonpregnant and not breastfeeding No AIDS opportunistic infection within 30 days of screening Subject with an HIV primoinfection status Recent history of drug and/or alcohol abuse History of psychiatric illness If presence of the following mutations : in the protease : one among 32,47,48,50,82,84,90 OR more than 3 mutations from the other points of the LPV mutation score:10,20,24,46,53,54,63,71 in the reverse transcriptase : 215 or 184. If abnormal laboratory results such as : Hb&lt;8 g/dl Absolute neutrophil count&lt;750 cells/µl Platelet count&lt;50 000/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>